CDSCO Panel Approves New Indications for Novo Nordisk’s Semaglutide, Mandates PMS Study
New Delhi: Recommending to conduct post marketing surveillance (PMS) study in India, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to the drug major Novo Nordisk India for the additional indication of the drug Semaglutide Injection 0.25 mg, 0.5 mg, and 1 mg. The additional indications […]